[go: up one dir, main page]

PE20190566A1 - Aumento de la fertilidad en especies bovinas - Google Patents

Aumento de la fertilidad en especies bovinas

Info

Publication number
PE20190566A1
PE20190566A1 PE2019000260A PE2019000260A PE20190566A1 PE 20190566 A1 PE20190566 A1 PE 20190566A1 PE 2019000260 A PE2019000260 A PE 2019000260A PE 2019000260 A PE2019000260 A PE 2019000260A PE 20190566 A1 PE20190566 A1 PE 20190566A1
Authority
PE
Peru
Prior art keywords
fertility
increase
bovine species
immunomodulation
immunogen
Prior art date
Application number
PE2019000260A
Other languages
English (en)
Inventor
Jason Nickell
Daniel Keil
Albert Abraham
Warren Tully
Riekerink Richard Gerhardus Martinu Olde
Terry Settje
Leland Vickers
Stuart Nibbelink
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20190566A1 publication Critical patent/PE20190566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones y metodos de inmunomodulacion que son eficaces para aumentar el porcentaje de concepcion de vacas. La composicion inmunomoduladora comprende un vehiculo de administracion de liposomas cationicos y una molecula de acido nucleico derivada de bacterias aisladas que no codifica para un inmunogeno
PE2019000260A 2016-07-26 2017-07-25 Aumento de la fertilidad en especies bovinas PE20190566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
PE20190566A1 true PE20190566A1 (es) 2019-04-22

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000260A PE20190566A1 (es) 2016-07-26 2017-07-25 Aumento de la fertilidad en especies bovinas

Country Status (22)

Country Link
US (1) US10933131B2 (es)
EP (1) EP3490598A1 (es)
JP (1) JP2019525935A (es)
KR (1) KR102473370B1 (es)
CN (1) CN109689095B (es)
AR (1) AR109167A1 (es)
AU (1) AU2017301528A1 (es)
BR (1) BR112019001599A2 (es)
CA (1) CA3031778A1 (es)
CL (1) CL2019000185A1 (es)
CO (1) CO2019000724A2 (es)
CR (1) CR20190037A (es)
DO (1) DOP2019000018A (es)
IL (1) IL264380A (es)
MX (1) MX386744B (es)
NZ (1) NZ750181A (es)
PE (1) PE20190566A1 (es)
PH (1) PH12019500191A1 (es)
SG (1) SG11201900710YA (es)
TW (1) TWI759317B (es)
UY (1) UY37346A (es)
WO (1) WO2018022583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CZ301488B6 (cs) * 1999-09-25 2010-03-24 University Of Iowa Research Foundation Použití imunostimulacních nukleových kyselin
EP1551221A4 (en) * 2002-07-03 2007-08-01 Coley Pharm Group Inc NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
CA2577270A1 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
MX336019B (es) 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
BR112013016231B1 (pt) 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2016207314A2 (en) 2015-06-26 2016-12-29 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
AU2016302436B2 (en) 2015-07-31 2022-03-03 Elanco Animal Health Gmbh Enhanced immune response in porcine species
EP3328423B1 (en) 2015-07-31 2021-05-26 Bayer Animal Health GmbH Enhanced immune response in fish

Also Published As

Publication number Publication date
IL264380A (en) 2019-02-28
TWI759317B (zh) 2022-04-01
TW201817427A (zh) 2018-05-16
CR20190037A (es) 2019-05-16
CL2019000185A1 (es) 2019-06-28
JP2019525935A (ja) 2019-09-12
KR20190032434A (ko) 2019-03-27
CA3031778A1 (en) 2018-02-01
MX2019001126A (es) 2019-08-14
EP3490598A1 (en) 2019-06-05
AR109167A1 (es) 2018-11-07
DOP2019000018A (es) 2019-07-31
CO2019000724A2 (es) 2019-02-08
KR102473370B1 (ko) 2022-12-05
PH12019500191A1 (en) 2022-04-11
US10933131B2 (en) 2021-03-02
NZ750181A (en) 2023-02-24
CN109689095A (zh) 2019-04-26
SG11201900710YA (en) 2019-02-27
US20190388538A1 (en) 2019-12-26
UY37346A (es) 2018-02-28
AU2017301528A1 (en) 2019-02-14
WO2018022583A1 (en) 2018-02-01
MX386744B (es) 2025-03-19
BR112019001599A2 (pt) 2019-10-01
CN109689095B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
BR102014027466A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de soja, método para preparação de uma célula de planta transgênica, e loci genômicos de soja não gênicos purificados
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
CO2017008455A2 (es) Anticuerpos contra tau
BR102014027442A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de maís, método de preparação de uma célula vegetal transgênica e loci genômicos de maís não gênico purificados
MX2017001279A (es) Usos y composiciones de la flagelina.
AR096869A1 (es) Neurotoxinas catiónicas
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
BR112017009988A2 (pt) xampus e condicionadores com efeito condicionador
MX2021007914A (es) Composiciones curables que comprenden poliolefinas insaturadas.
CL2018001546A1 (es) Formulaciones líquidas que contienen fungicidas
MX2020001885A (es) Formulaciones de daptomicina.
MX379120B (es) Silanos y composiciones curables que contienen dichos silanos como reticulantes.
MX2022011694A (es) Metodos para hacer agentes de contraste por ultrasonido.
MX2017010037A (es) Metodos de tratamiento de enfermedades inflamatorias.
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
ZA201901168B (en) Novel compounds for treating parasitic disease
ECSP18024466A (es) Composiciones de micropartículas que comprenden saflufenacil
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
DOP2019000102A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
PE20190566A1 (es) Aumento de la fertilidad en especies bovinas
EA201892003A1 (ru) Лечение атопического дерматита собак
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CO2017001320A2 (es) Composición de lhrh inmunogénica